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M2e is the external domain of the influenza A M2-protein. It is minimally immunogenic during infection and conventional vaccination,
which explains in part its striking sequence conservation across all human influenza A strains. Previous research has shown that when M2e is
linked to an appropriate carrier such as hepatitis B virus core (HBc) particles, it becomes highly immunogenic, eliciting antibodies that fully
protect mice against a potentially lethal virus infection. Different M2e-HBc particles and adjuvants suitable for human use were compared for
induction of protective immunity. Strong immunogenicity and full protection were obtained after either intraperitoneal or intranasal
administration. The most protective particle contained three consecutive M2e-copies linked to the N-terminus of HBc. Although HBc is
highly immunogenic, the optimized M2e-HBc vaccine induced an anti-M2e antibody titer even higher than that of anti-HBc.
D 2005 Elsevier Inc. All rights reserved.Keywords: Influenza A; M2-protein; Hepatitis B virus; HBV core; M2e-HBcIntroduction
Influenza virus typically infects 10–20% of the total
worldwide population during seasonal epidemics, resulting
in three to five million cases of severe illness and 250,000 to
500,000 deaths per year (Anonymous, 2003). In the US,
influenza kills an average of 20,000 people per year, while
an average of 114,000 influenza-related hospitalizations
result in an estimated economic cost of $12 billion per year
(Poland et al., 2001). Moreover, novel influenza strains
appear occasionally in the human population, causing
pandemics. The death toll of the 1917–1920 Spanish Flu
pandemic resulted in over 50 million deaths worldwide
(Johnson and Mueller, 2002), and the danger of a new
influenza pandemic is always present.
Nowadays, conventional vaccines contain antigenic
determinants from three virus strains, two A-strains and
one B, predicted to be the most likely to cause the next
epidemic. They are dosed on the basis of their hemagglu-0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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* Corresponding author. Fax: +32 9 2280883.
E-mail address: fiers@dmbr.UGent.be (W. Fiers).tinin (HA) content, the major glycoprotein of the virus.
Approximately 250 million doses of influenza vaccine are
produced each year (Gerdil, 2003), with protective efficacy
in children and adults ranging between 60% and 90% (Cox
and Subbarao, 1999). Although these vaccines are less
effective in the elderly, 80% of influenza-caused deaths in
this age group are prevented (Patriarca et al., 1985).
However, conventional vaccines have important drawbacks,
the most important of which is the uncertainty in the choice
of virus strains to be included in each year’s vaccine
formulation. Over a 10-year period, the match between
predicted and circulating strains was correct in 88% of cases
(Palache, 1992), but inaccurate predictions can greatly affect
vaccine efficacy. In the 1997–1998 winter season, for
example, efficacy of vaccination against serologically
confirmed influenza illness was reduced to 50% (Bridges
et al., 2000). During the 2003–2004 season, the A/Panama/
2007/99 strain, a component of the conventional vaccines,
did not satisfactorily match the related, prevalent, circulating
strain A/Fujian/411/2002. An even greater threat, however,
exists in the form of transmission of highly virulent avian
influenza viruses from birds to humans, as occurred in Hong05) 149 – 161
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East countries in 2003–2004 and the ongoing 2004–2005
winter season (Claas et al., 1998; Normile, 2004; Peiris et
al., 1999; Suarez et al., 1998). 45 cases of avian H5N1
transmission to humans were identified in 2004, of which 32
were fatal (Anonymous, 2004). These rare infections in
humans may, by gene reassortment, give rise to novel
human influenza A strains with pandemic potential. In
addition to the uncertainty associated with strain prediction,
conventional vaccine production has inherent deficiencies.
These vaccines are produced by growing virus in embryo-
nated chicken eggs or tissue culture, procedures which are
not without potential pitfalls and uncertainties. These
shortcomings are related to, for instance, adequacy of egg
supply, appropriateness of virus inoculating stocks, bio-
logical safety, residual avian proteins, killing of chicken
embryos by highly virulent avian viruses, etc. (Normile,
2004; Webby et al., 2004).
In view of the inherent limitations in the approved,
conventional influenza vaccines, we have taken a
completely different approach, based on the highly
conserved, extracellular domain of the viral M2-protein
(M2e). The M2-protein is a tetrameric, type III trans-
membrane protein scarcely present on virus particles, but
abundant on virus-infected cells (Lamb et al., 1985;
Holsinger and Lamb, 1991; Pinto et al., 1992). The
human influenza A M2e-sequence is only 23 amino acids
long. It has remained nearly unchanged since the first
human influenza strain was isolated in 1933, despite
numerous epidemics and two major pandemics since then
(Fiers et al., 2004; Neirynck et al., 1999). By linking
M2e to a carrier, such as the hepatitis B Virus core
particle (HBc), the sequence can be presented in a much
more immunogenic form to the immune system. Anti-
bodies produced after vaccination with M2e-HBc particles
fully protect mice against a potentially lethal challenge by
a mouse-adapted influenza strain (Neirynck et al., 1999).
Procedures for expression and purification of M2e-HBc
are straightforward, efficient, and reproducible. Because
the M2e-HBc material is made in Escherichia coli, safety
concerns often associated with preparations derived from
eukaryotic expression systems are avoided. In view of the
conserved nature of the target sequence, human influenza
A M2e, we can refer to this system as a ‘‘universal
vaccine’’ (Neirynck et al., 1999). Further experiments
documenting the universality of the vaccine for all
human-transmissible influenza A viruses are ongoing.
We previously published the proof of concept for this
M2e-based influenza A vaccine and demonstrated that the
protection elicited was due to antibodies/humoral immune
responses as it was transferable by serum (Neirynck et al.,
1999). Since then, we have carried out experiments whereby
various parameters were evaluated, such as different
molecular constructs, adjuvants, and routes of administra-
tion. These efforts have led to an improved vaccine
candidate, as here described.Results
Protection against a lethal influenza A infection can be
achieved when the M2e-antigen is genetically linked to the
N-terminus or inserted in the immunodominant loop of
C-terminally truncated HBc particles
We previously reported protection of mice against a
potentially lethal influenza A infection using a vaccine
consisting of full-length HBc particles with M2e genetically
fused to the N-terminus of the HBc-subunits (Neirynck et
al., 1999). As no modifications are made at the N-terminus
of M2e, it remains as it is in the native influenza A M2-
protein. The icosahedral HBc-particle consists of 240
monomers, arranged as dimeric building blocks (Wynne et
al., 1999). The particle carries 120 spikes on its surface,
each of which consists of two interacting a-helical loops
formed by the two partners of the dimer. These spikes are
highly immunogenic and can be used for insertion of foreign
B-cell epitopes (Kratz et al., 1999; Murray and Shiau, 1999;
Pumpens and Grens, 2001).
The M2e-HBc particle used previously (Neirynck et al.,
1999), now renamed particle 1559, contains the full-length
HBc protein, except for the first 4 amino acids, which are
replaced by M2e. The basic C-terminal domain of the HBc
protein, which is 34 amino acids in length, contains
protamine-like clusters and functions as an anchor to retain
the viral DNA in the particle. When produced in E. coli and
purified, this domain binds host RNA, which accounts for
approximately 25% of the particle weight (Wingfield et al.,
1995). Although these contaminants may contribute to the
immunogenicity by acting as adjuvants, they negatively
impact yields and complicate the rigorous chemical charac-
terization of the vaccine preparation. Because the basic
C-terminal domain (amino acids 150–183) is not needed for
HBc particle assembly (Zheng et al., 1992), it was deleted
from particle 1473, and a Cys residue was added (position
150) to increase stability (Birkett, 1999). M2e contains two
Cys-residues at positions 17 and 19. It is conceivable that
these cysteines could result in aggregation under oxidative
conditions by the formation of inter-particle disulfide bonds.
Therefore, the two Cys residues in M2e were replaced by
Ala in particle 1473 (replacement in all later particles was
by Ser, which better mimics Cys).
In our earlier experiments (Neirynck et al., 1999),
vaccination with particle 1559 (previously referred to as
IM2HBc), administered either intraperitoneally (i.p.) with
‘‘MPL-TDM emulsion/MPL-MDP’’ as adjuvant, or intra-
nasally (i.n.) without adjuvant, fully protected mice
against a potentially lethal infection with mouse-adapted
(m.a.) influenza A (strain X47). Therefore, these experi-
ments were repeated as positive controls. The results,
shown in Fig. 1, confirm that these formulations, indeed,
confer full protection. Moreover, vaccination with particle
1473 also resulted in complete protection. This means
that the M2e-peptide does not have to start with a free
Fig. 2. Seven groups of 14 BALB/c mice were vaccinated i.p. with particle
1473 or 1559 in absence or presence of adjuvant, Alhydrogel, or Montanide
ISA-720, as indicated, followed by challenge with 4 LD50 of m.a. X47
virus (cf. Materials and methods for further details). (A) Mortality after
challenge. (B) Percent of initial body weight after challenge (with standard
error bars).
Fig. 1. Survival of vaccinated BALB/c mice after challenge with 4 LD50 of
m.a. X47 influenza A virus. The experiment involved 4 groups of 14 female
mice, 8 weeks old. Three immunizations with 10 Ag vaccine per mouse
were given at 3-week intervals. Mice were challenged 3 weeks after the last
boost. Particles 1559 and 1473 (Table 1) were administered i.p. in
combination with MPL-TDM emulsion (priming) followed by MPL-
MDP (boosters) as adjuvant. Particle 1559 was also administered i.n.
without adjuvant (cf. Materials and methods and Neirynck et al., 1999 for
further details).
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terminal domain of the HBc subunit is dispensable, and
that the Cys-residues in the M2e-sequence can be
replaced by residues of similar size.
Particles 1559 and 1473 confer full protection when
administered i.p. with different adjuvants
The most commonly used adjuvants in approved
human vaccines are aluminum salts, namely aluminum
hydroxide and aluminum phosphate. Although this class
of adjuvants has a long record of safety, their efficacy
has been surpassed by new types of adjuvants. One of
these is Montanide ISA-720, a water-in-non-mineral oil
emulsion that has been studied in human Phase I and
Phase II clinical trials (Aucouturier et al., 2002, and
Seppic data sheet P/1755/GB/01/July 2001—Revised
August 3, 2001). We evaluated the effects of particles
1559 and 1473 alone, adsorbed on Alhydrogel, or in
combination with Montanide ISA-720. When formulated
with adjuvants, each of these particles provided complete
protection against a potentially lethal challenge infection
(Fig. 2A). In the absence of adjuvant, protection was still
complete for particle 1559 but only partial for 1473; the
difference in survival was significant (Kaplan–Meier
method, P < 0.05).
In all experiments, morbidity following challenge was
monitored by measuring weight and rectal temperature.
There was usually a weight loss after challenge, even in
the fully protected groups. As discussed previously
(Neirynck et al., 1999), the incomplete prevention of
morbidity may be explained by the severity of thechallenge. A highly lethal dose for challenge ensures
that all, or nearly all, control animals will die as a
consequence, and unambiguously confirms the protective
efficacy of the vaccine. But it should be stressed that this
strong challenge dose results in a much more abrupt and
intense illness than humans are likely to experience when
naturally infected. It may be noted in this respect that a
conventional, HA-based vaccine, tested in mice in a
similar vaccination/lethal challenge model as used here,
was protective but was also unable to alleviate morbidity
as monitored by weight loss (Huber et al., 2001). The
data presented in Fig. 2B reveal that immunization in the
presence of adjuvant does not prevent morbidity but
significantly reduces it (Tukey test, P < 0.05 for
adjuvanted relative to unadjuvanted vaccination; data for
day 8). Additionally, Fig. 2B suggests that Montanide
ISA-720 may be slightly superior to Alhydrogel in
reducing morbidity, but the difference between the two
adjuvants was not statistically significant. Similar con-
clusions about morbidity could be drawn from the body
temperature data (not shown).
We also monitored the anti-M2e immune response by
determining the titer of the various M2e-specific IgG
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was considerably enhanced by the inclusion of an adjuvant in
the vaccine preparation, especially Montanide ISA-720 (Fig.
3A). For example, both for particles 1559 and 1473, the
serum titers obtained after boost 2 for the Montanide ISA-
720 and Alhydrogel-adjuvanted groups were significantly
higher than the titers obtained for the unadjuvanted group
(Tukey multiple comparison of means test at 95% confidence
level). It may be noted that the IgG1 titer after two boosts
with M2e-HBc particles formulated with Montanide ISA-
720 was so high that it was not enhanced further by the
challenge infection. In Fig. 3B, the IgG2a data are shown.
We have previously reported that protection seems to
correlate with a high IgG2a titer, which suggests that a
T-helper cell type 1 response is needed for efficient
protection (Fiers et al., 2004). Therefore, it is of interest to
note that particle 1473, which provided only partial
protection in the absence of adjuvant (Fig. 2A), had induced
only a fairly weak IgG2a response. Conversely, the IgG1 titer
after the second boost of particle 1473 in saline was higher
than that of 1559 in saline (Fig. 3A; difference not statisti-
cally significant). To conclude, the analysis of humoral
immune responses correlates with the morbidity data. For
both particle 1473 and 1559, IgG1 and IgG2a titers after the
second boost were higher in combination with Montanide
ISA-720 than with Alhydrogel.Fig. 3. M2e-specific IgG subclasses in pooled sera from mice used in the
experiment shown in Fig. 2. (A) IgG1. (B) IgG2a (similar titers were
obtained for IgG2b).In combination with adjuvants appropriate for human use,
particles 1604 and 1569 provide complete protection
against a potentially lethal influenza challenge
Particle 1604, like particle 1559, contains the M2e
sequence fused to the N-terminus of the HBc subunit, but
the C-terminal basic domain (34 amino acids) was replaced
by a single Cys residue. Particle 1569 is identical to the
aforementioned 1473, except that the two M2e cysteines
were replaced by serines, rather than alanines. Particles 1604
and 1569 were formulated on Alhydrogel, Alhydrogel + RC-
529-AF, or ‘‘MPL-TDM emulsion/MPL-MDP’’ used pre-
viously (Neirynck et al., 1999). RC-529-AF is a well-
defined, synthetic compound based on natural, detoxified
lipopolysaccharide A (Evans et al., 2003).
The results of the vaccination/challenge experiment,
shown in Fig. 4A, reveal that both vaccine particles, in
combination with either adjuvant, fully protected mice
against a potentially lethal infection. The few control mice
that survived experienced severe weight loss and drop of
body temperature before recovering. The survival of these
mice may be due to activation of the innate immune system
by MPL that can induce nonspecific resistance against viral
pathogens like influenza (Persing et al., 2002).
The M2e-specific IgG1 immune responses induced by
the two types of particles were similar (Fig. 4B), meaning
that positioning M2e at the N-terminus (1604) or internally
in the immunodominant loop (1569) of the HBc subunit
does not appreciably affect the immunogenicity of the M2e
peptide. Addition of RC-529 enhanced the adjuvant effect
of Alhydrogel such that it reached the same level as
observed using MPL-TDM emulsion (priming) and MPL-
MDP (boosters) in previous studies (Neirynck et al., 1999).
In groups treated with particles adsorbed on Alhydrogel, no
further increase in titer was observed when a second boost
was administered. It is interesting to note that the M2e-
antibody titer in the few surviving, non-vaccinated mice was
barely detectable after challenge, highlighting the low
immunogenicity of natural M2-protein.
M2e-HBc vaccine also provides complete protection when
administered intranasally, and efficacy is considerably
enhanced by using detoxified enterotoxin adjuvant
Nasal administration of vaccines targeting respiratory
infections has several important advantages. Many people
have a fear of injection needles, and nasal administration
can be delivered safely and with minimal effort to a large
group of subjects. Moreover, as influenza is a respiratory
disease, it is likely that i.n. vaccination preferentially
stimulates the lymphoid system associated with the upper
respiratory tract and enhances local immunity (Liang et al.,
2001; Tamura et al., 1998).
We have shown previously that an M2e-HBc vaccine can
protect efficiently when administered i.n. (Neirynck et al.,
1999, and Fig. 1). Here we report that the induced immune
Fig. 5. Vaccination by i.n. administration and effect of detoxified mutant
enterotoxin as adjuvant. Mice were immunized 3 times i.n. with either PBS
(control), unadjuvanted 1559, or 1559 adjuvanted with 5 Ag LTR192G. (A)
Survival after challenge with 4 LD50 of m.a. X47. (B) Percent of initial
body weight after challenge (with standard error bars).
Fig. 4. Six groups of 15 BALB/c mice were vaccinated i.p. with no protein,
particle 1604 or 1569 in combination with adjuvant (MPL-TDM emulsion/
MPL-MDP, Alhydrogel, or Alhydrogel plus RC-529-AF); controls received
an injection of buffer. Mice were challenged with 4 LD50 of m.a. X47 virus
(cf. Materials and methods for further details). (A) Post-challenge survival
of control mice and M2e-HBc vaccinees after challenge. (B) M2e-specific
IgG1 titers in sera of BALB/c mice after vaccination with particle 1569 or
1604 in combination with different adjuvants.
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adjuvant suitable for i.n. delivery. J. Clements has charac-
terized an E. coli heat labile enterotoxin mutant, LTR192G,
that has lost nearly all toxicity but has retained its potent
adjuvancy (Dickinson and Clements, 1995; Freytag and
Clements, 1999). Whereas the unadjuvanted M2e-HBc
vaccine (particle 1559) provided almost complete protection
(Fig. 5), addition of LTR192G increased survival to 100%
(the difference was not significant, according to the
Kaplan–Meier method), and dramatically elevated the
M2e-specific antibody titers in circulation (Table 2). Indeed,
the IgG1, IgG2a, and IgG2b titers were all significantly
increased by addition of LTR192G (two-sample t test, P <
0.005). Moreover, morbidity was almost completely abol-
ished in the adjuvanted group (Fig. 5B; P < 0.05 on days 6
and 8, two-sample t test). Similar results were obtained
using particles 1569 and 1604 (data not shown). We
observed consistently that i.n. immunization resulted in anevident IgA response in circulation, which did not occur
after i.p. immunizations.
Constructs with multiple, consecutive M2e-sequences
induce an enhanced immune response that leads to strong
protection
Jegerlehner et al. (2002) have described an M2e-HBc
particle, referred to as M2-VLP, made by chemical linkage
of the M2e-peptide to the immunodominant loop as an
alternative to genetic fusion to the N-terminus. This required
prior modification of the HBc particle by insertion of an
acceptor lysine residue in the subunit loop, as previously
described (Birkett, 1999). Jegerlehner et al. (2002) reported
that this M2-VLP particle provided better protection than an
1559-like particle constructed according to our earlier
description (Neirynck et al., 1999). Because insertion of
the M2e-peptide in the immunodominant loop did not
significantly enhance immunogenicity (particles 1473 and
1569, discussed above), we produced particles with two
(1817) and three (1818) M2e-copies fused to the N-terminus
of HBc subunits. These new constructs were compared to
particle HBc/K77-M2e, which, like M2-VLP (Jegerlehner et
al., 2002), was made by chemical fusion of an M2e-
sequence to a lysine residue introduced into the immunodo-
minant loop of HBc particle subunits.
The results of a vaccination/challenge experiment are
shown in Fig. 6. In this experiment, we used buffer (PBS),
Fig. 6. Survival and morbidity of control mice and M2e-vaccinees after
challenge with 4 LD50 of m.a. X47. All mice received three i.p. injections;
particles 1123 (HBc control), 1604, 1817, 1818, and HBc/K77-M2e were
formulated with Alhydrogel plus RC-529-AF as adjuvants. (A) Survival.
(B) percent of initial body weight after challenge (with standard error bars).
Fig. 7. M2e-specific IgG1 and IgG2a titers in sera of mice after
immunization (mice from same experiment referred to in Fig. 6). (A)
IgG1. (B) IgG2a.
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Protection after vaccination with 1817, 1818, and HBc/
K77-M2e was complete while 2 of 12 mice in the 1604
group died (the lower rate of survival of this group was not
significantly different from the 1817, 1818, and HBc/K77-
M2e groups; Kaplan–Meier method) (Fig. 6A). Morbidity
was reduced (Fig. 6B), although not statistically signifi-
cantly. The IgG1 titers were remarkably high and almost
identical in sera of animals immunized with particles 1817,
1818, and HBc/K77-M2e (Fig. 7A). These titers were
significantly higher than those obtained for group 1604
(Tukey test, P < 0.05). IgG2a titers were also almost
indistinguishable for the former three particles and again
significantly higher than those of the 1604 group (Fig. 7B;
Tukey test, P < 0.05). As 10 Ag M2e-vaccine wasTable 1
Designation of the different vaccine particles used in the present studya
N-terminal fusion HBc NH2-terminus
1123 None 1
1559 M2(1–24) 5
1473 None 1
1569 None 1
1604 M2(1–24) 5
1817 M2(1–24/2C > 2S)-M2(2–24) 5
1818 M2(1–24/2C > 2S)-M2(2–24/2C > 2S)-M2(2–24) 5
a The position of the M2e-copy in the HBc carrier, the nature of endogenous M2e
use of each particle in experiments shown in the figures are indicated.administered per mouse per injection, it follows that mice
treated with particle 1817 received about twice the molar
concentration of M2e-peptide compared to those treated
with 1604, whereas mice treated with 1818 received about
three times the molar concentration per injection. We have
shown previously that there is only a limited dose/response
correlation in the range 5–50 Ag vaccine/injection/mouse
(Neirynck et al., 1999). Therefore, the higher immune
response induced by particles 1817 and 1818 when
compared to particle 1604 (e.g., 10-fold higher IgG2a afterstart Immunodominant loop fusion C-terminus end Results shown in
None 150 Figs. 6 and 7
None 183 Figs. 1, 2, 3, and 5
M2(1–24/2C > 2A) 150 Figs. 1, 2, and 3
M2(2–24/2C > 2S) 150 Fig. 4
None 150 Figs. 4, 6, 7, and 8
None 150 Figs. 6, 7, and 8
None 150 Figs. 6, 7, and 8
cysteine replacements, the position of the C-terminus of the carrier, and the
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but rather reflect enhanced immunogenicity of these
particles. In nearly all previous experiments, the IgG2b
titers (not shown) were approximately the same as the
IgG2a titers, but in the present experiment the IgG2b titers
elicited by particles 1817 and 1818 exceeded the IgG2a
titers. In the control groups (buffer or HBc plus adjuvant),
neither protection nor M2e-specific immunoreactivity could
be detected, supporting the specificity of the assays used.
In most experiments in this study, anti-HBc immune
responses were also measured in all groups of mice. HBc is
a potent immunogen by itself, which is the reason for its
frequent use as a carrier for foreign epitopes (Kratz et al.,
1999; Murray and Shiau, 1999; Pumpens and Grens, 2001).
The immune response is mainly directed against the spikes
(Salfeld et al., 1989; Wynne et al., 1999), which allow
efficient interaction with B-cell receptors by virtue of their
position and spacing. Indeed, we observed a strong immune
response to HBc in nearly all experiments. As expected,
particles containing an insertion in the immunodominant
loop (1473 and 1569) had about a 10-fold lower anti-HBc
response, indicative of disruption of major B-cell epitopes.
We measured not only total HBc-specific antibodies, but
also IgG1, such that the immune response could be directly
compared to the anti-M2e data. For the most immunogenic
particles, the anti-M2e response after the second boost
equaled (particle 1817) or even surpassed (particles 1818
and HBc/K77-M2e) the anti-HBc response (Fig. 8). The
anti-HBc IgG1 titer declines in the order 1604 > 1817 >
HBc/K77-M2e > 1818. A similar pattern was observed for
total IgG. In particle HBc/K77-M2e, the immunodominant
loop had been modified by a substitution, which may
explain the lower HBc immunogenicity relative to particle
1604. But the HBc spikes of particles 1817 and 1818
remained unchanged, which means there must be another
reason for the reduced anti-HBc response to these particles.Fig. 8. Comparison of IgG1 response directed to either M2e or HBc in sera
of vaccinated BALB/c mice after the second boost (sera from same
experiment as shown in Fig. 6).Particles 1604 and 1818 were also compared in an
experiment involving only two immunizations. All the mice
vaccinated with 1818 were protected against a lethal
challenge while three out of ten 1604-vaccinated mice
succumbed to the viral challenge (Table 3; the difference in
survival was significant, P < 0.05 by the Kaplan–Meier
method). The IgG1 and IgG2a titers in the 1818-vaccinated
group were significantly higher than the titers obtained for
the 1604-vaccinated mice (P < 0.025, two-sample t test).
Four more mice from each group were euthanized on day 3
post-challenge to determine the extent of virus replication in
the lungs. Three days after challenge, the 1818-vaccinated
mice had 10-fold lower titers of virus in their lungs
compared to the 1604-vaccinated mice (Table 3).Discussion
The hallmark of influenza virus is the remarkable
variability of its major surface glycoproteins, HA and NA,
which allows the virus to evade existing anti-influenza
immunity in the target population. Amino acids exposed on
the outside of these major antigenic determinants can mutate
almost at random without destabilizing the scaffold of the
protein or interfering with the active center, sialic acid
receptor, and neuraminidase activity, respectively. M2e, a
small peptide localized close to the membrane of the virus
and the infected cells, is presumably shielded from efficient
interaction with immune effector cells. Indeed, despite
frequent exposure to influenza infections, antibodies direc-
ted towards M2e are absent or barely detectable in the serum
of humans (Black et al., 1993, Liu et al., 2003). Clearly,
M2e does not take part in the drift/shift versus population
immunity competition. This is one of the reasons why the
sequence has remained nearly unchanged since the first
human influenza A strain was isolated in 1933. When an
occasional mutation did occur, as in the PR8-strain, it was
inconsequential for the induced protective immunity (Neir-
ynck et al., 1999). In addition, M2e sequence conservation
may also be imposed by its genetic link to a second protein.
The influenza A segment 7 codes for both M1- and M2-
protein, which are produced by differential splicing (Lamb
et al., 1981). The result is that the first 9 amino acids of
M2e, including the initiator methionine, are shared with M1
and, therefore, function in two capacities. The next 15
amino acids of M2e are coded for by a segment of RNA
that is also translated in a different reading frame to
produce the C-terminal sequence of M1-protein. Again, the
dual function of this RNA-sequence segment severely
constrains possible mutations. M2e is, therefore, an ideal
target for a broad-spectrum, recombinant influenza A
vaccine, as it is almost completely conserved across all
human virus strains.
We have reported previously that M2e becomes highly
immunogenic when linked to an appropriate carrier such as
hepatitis virus B core, resulting in protection against a
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1999). This protection is due to antibodies as it is
transferable by passive immunization (Neirynck et al.,
1999). The HBc particle is an excellent carrier for a number
of reasons. It is highly immunogenic (Salfeld et al., 1989;
Wynne et al., 1999), is both a T cell-independent and a T
cell-dependent antigen (Milich and McLachlan, 1986),
exhibits a lack of genetic restriction (Milich and McLachlan,
1986), and is able to transfer these attributes to fused
epitopes (Ulrich et al., 1998). In addition, HBc particles are
remarkably tolerant to modifications such as substitutions,
additions, and deletions, making it a versatile carrier of
heterologous epitopes (Kratz et al., 1999; Murray and Shiau,
1999; Pumpens and Grens, 2001; Ulrich et al., 1998).
Furthermore, HBc particles can be produced efficiently in E.
coli, obviating the need for biological materials that may be
in short supply or may contain biohazards.
As mentioned above, we routinely used a fairly severe
viral challenge to evaluate the efficacy of the M2e-based
vaccination. Though this challenge with a highly lethal
dose is undoubtedly more severe than a person encounters
upon natural infection, it has the advantage that a clear-cut
protection against mortality can be demonstrated. It may be
noted that the challenge conditions used by various authors
to score protection after vaccination with an M2e-based
vaccine vary widely. A mild challenge dose does not allow
to score for survival, but the protection can be assayed,
e.g., by reduction of virus titer in lung homogenates. Frace
et al. (1999) used 100 MID50 of a m.a. flu strain for
challenge, and Mozdzanowska et al. (2003) administered
1000 MID50 of a low pathogenic flu strain. The ratio LD50/
MID50 varies according to the virus preparation, but the
latter authors reported that 1000 MID50 corresponded to
0.01 LD50. In contrast, in the present study, we used mostly
4 LD50, which is in range of those used by other
investigators who also scored for mortality, viz. 10 LD50
by Jegerlehner et al. (2002) and 1 LD90 by Fan et al.
(2004). These differences in vaccine dose and in influenza
strain used for challenge preclude meaningful comparison
of the effectiveness of the various M2e-vaccines reported
by different investigators.
In order to improve the M2e-HBc vaccine, we removed
the C-terminal domain, which normally interacts with the
internal viral nucleic acid. A single cysteine residue was
added to the C-terminus of HBc. This resulted in higher
expression levels, more easily characterized particles, and
increased purity of the final product. Removal of the C-
terminal nucleic acid binding domain did not affect the
protective efficacy of the particles. Also, Jegerlehner et al.
(2002) used particles derived from HBc lacking the basic C-
terminal domain. In some particles, the two cysteine
residues in M2e were replaced by other small residues such
as alanine or serine to avoid potential protein aggregation by
disulfide bridging (Table 1); these substitutions had no
detectable effect on efficacy of protection or immunoge-
nicity. As mentioned above, the spikes on the HBc particlesare the major antigenic determinants. Nevertheless, insertion
of the M2e-sequence in the spike loop (particles 1473 and
1569) did not improve the efficacy relative to the particles
with an M2e-sequence fused to the N-terminus. Possibly, a
more constrained conformation of the insert could limit the
potential benefit of enhanced accessibility.
Adjuvants stimulate innate immunity, and, when co-
administered with an antigen, boost immunogenicity. The
result is not only a much enhanced cellular and humoral
immune response, but also a biasing of the responses
towards either a more Th-1 or a more Th-2 type immunity,
depending on the adjuvant used. The Th immunity type is
indicated by the relative levels of induced immunoglobulin
isotypes, IgG1, which is indicative of Th-2 activity versus
IgG2a and IgG2b, both indicative of Th-1 effects. In
previous studies involving i.p. administration, we used
MPL-TDM emulsion for priming, followed by MPL-MDP
for booster injections (Neirynck et al., 1999). Alhydrogel is
the most widely used adjuvant in human vaccines. It has a
long record of safety, but it does not have the efficacy of
other, newer adjuvants. Alhydrogel functions mainly by
prolonging the half-life of adsorbed antigens in vivo.
Adjuvants such as MPL and CpG oligonucleotides are
derived from natural pathogens and their mechanism of
action involves stimulation of specific Toll-like receptors
(TLR) on immune effector cells. Further characterization of
MPL led to the synthetic RC-529, which has already been
used in a number of clinical trials (Persing et al., 2002). It
retains the high efficacy of MPL but its side-effect profile is
similar to that of Alhydrogel. The results reported here show
that Alhydrogel provides important adjuvant effects to
adsorbed M2e-HBc particles, but that this activity can be
further enhanced by other adjuvants such as RC-529, which
directly targets the TLR4 Toll-like receptor (Evans et al.,
2003). Unlike the TLR agonists, Montanide ISA-720 is a
water-in-oil emulsion that is believed to function as a
reservoir, slowly releasing the antigen, and facilitates the
uptake of antigen by antigen presenting cells (Aucouturier et
al., 2002). As both types of adjuvants have already been
used in human clinical trials, they are obvious candidates for
further development as possible components of a universal
flu vaccine.
There is widespread interest in needle-free vaccination as
many people have an aversion to needle injection. Vaccines
can be safely and rapidly administered to a large number of
recipients through the i.n. route, which may be more
efficient in stimulating nasal lymphoid tissues and leads to
improved mucosal immunity in the respiratory tract region
(Liang et al., 2001; Tamura et al., 1998). E. coli and Vibrio
cholerae enterotoxins are very potent adjuvants for oral and
nasal administration, but their toxicity limits their applica-
tion. However, mutants such as LTR192G that have much
reduced toxicity while retaining adjuvancy have been
generated by site-directed mutagenesis (Dickinson and
Clements, 1995; Freytag and Clements, 1999). LTR192G
has been used extensively as an adjuvant for oral and
Table 3
Survival, lung virus titer, IgG1 titer, and IgG2a titer of mice immunized
twice with M2e-vaccine and challenged with m.a. influenza A virusa
Vaccineb Survivalc Lung virus titerd IgG1e IgG2ae
PBS 0/10 4.23 0 0
1604 7/10 3.33 2700 300
1818 10/10 2.26 218,700 8100
a Fourteen mice were immunized twice intranasally at 3-week intervals
with 10 Ag M2e-vaccine formulated with 1 Ag LTR192G.
b Control (PBS) and M2e-vaccine particles.
c Number of surviving mice over a 14-day post-challenge period.
d Four mice were euthanized 3 days post-challenge, and lung virus titers
were determined (expressed as mean log10 EID50/ml).
e IgG-isotype M2e-antibody titers of serum samples collected 14 days after
the second immunization.
M. De Filette et al. / Virology 337 (2005) 149–161 157intranasal vaccination in experimental animals, including in
combination with conventional influenza vaccines (Lu et al.,
2002; Tumpey et al., 2001). It has also been tested in several
clinical trials (Kotloff et al., 2001; Losonsky et al., 2003). In
agreement with previous results (Neirynck et al., 1999),
M2e-HBc administered i.n. leads to effective protection
(Figs. 1 and 5A), but the addition of LTR192G provides a
more solid protection in terms of mitigating morbidity (Fig.
5B) and considerably enhancing the titers of IgG1, IgG2a,
and IgG2b (Table 2). IgA was also clearly present in
circulation, but at levels presumably too low to play a
significant role in protection; its presence, however,
confirms induction of localized, mucosal immunity. IgA
was not detected in circulation when the i.p. vaccination
route was used.
A major improvement of the vaccine particle was
achieved when the copy number of M2e at the N-
terminus was increased from 1 to 2 or 3 (particles 1604,
1817, and 1818, respectively). Repeats of B-cell epitopes
have often been used to increase the immune response to
vaccines, including for M2e-based vaccines (Liu et al.,
2004; Neirynck et al., 1997). By using 2 and a fortiori 3
copies of M2e instead of one, more complete protection
was achieved against mortality and morbidity after a
severe challenge. But the effect is most quantifiable by
considering the IgG titers. After the second immunization
with particle 1817 or 1818, the titers of IgG1 and IgG2a
increased by a factor of 80 and 30, respectively, over
those observed using the 1604 particle. There was an
inverse correlation with the HBc titers, which decreased
in the order 1604 > 1817 > 1818 (Fig. 8). This is
remarkable as most of the HBc immune response is
directed toward the immunodominant loop (Kratz et al.,
1999; Pumpens and Grens, 2001; Wynne et al., 1999),
which remained intact in these three particles. It is
possible that the longer extension of the N-terminus
physically interferes with access of immune effector cells
to the normally immunodominant HBc spikes. Alterna-
tively, there may be competition between the anti-HBc
specific B-cells and the more abundant anti-M2e-specific
cells for cytokines and other growth factors; this may
deprive the former of optimal growth and stimulatory
factor concentrations. The end result is that the immune
response against M2e, as it is displayed in particles 1817Table 2
IgG1, IgG2a, IgG2b, and IgA M2e-antibody titers in serum collected after
the second boosta
IgG1 IgG2a IgG2b IgA
Control (PBS) <100 <100 <100 <100
1559 100 300 300 100
1559 + LTR192G 72,900 72,900 72,900 300
a Pooled serum from control mice (PBS treated), mice treated with particle
1559 alone, and mice treated with 1559 in combination with 5 Ag LTR192G
was analyzed. All vaccinations were i.n. Same mice from experiment
shown in Fig. 5.and 1818, is even stronger than against the highly
immunogenic HBc. It may be noted here that the immune
response to HBc is at least 80-fold, and in BALB/c mice
even 300-fold higher than against the envelope antigen
HBs, which is the basis for the highly effective and
successful vaccine against human hepatitis B virus
infection (Milich and McLachlan, 1986). We also found
that the 1818 vaccine is capable of conferring complete
protection after only 2 injections instead of 3 (Table 3).
Jegerlehner et al. (2002) reported that a modified HBc
particle displaying an M2e peptide chemically coupled to
the immunodominant loop induced a higher M2e-specific
immune response and was more protective in vivo than
an 1559-like particle made by genetic fusion according to
our previous description (Neirynck et al., 1999). The
results shown here demonstrate that the recombinant
particle 1818 is at least as immunogenic and protective
as the HBc/K77-M2e chemical conjugate, which was
made according to the description reported by the
aforementioned authors.
M2e is scarcely present on virus particles, but fairly
abundant on virus-infected cells (Lamb et al., 1985). It is
therefore more likely that the latter are the targets for
protective antibodies. The mechanism of protection by the
antibodies induced by M2e vaccination has not yet been
fully elucidated. Undoubtedly, NK-dependent antigen-
dependent cell cytotoxicity (ADCC) plays an important
role (Jegerlehner et al., 2004; De Filette et al.,
unpublished results). But other protective mechanisms
may also be involved.
In conclusion, the M2e-HBc vaccine can be adminis-
tered either parenterally or intranasally in combination
with an adjuvant; effective adjuvants suitable for human
clinical trials have been identified. The results reported
here document that vaccination of mice with an M2e-
HBc universal flu vaccine confers full protection against
a severe (4-fold 50% lethal dose) challenge with a
mouse-adapted influenza A strain. The optimized vaccine
particle, 1818, is clearly superior in terms of conferring
improved protection, reducing morbidity, decreasing virus
replication in the lungs, and inducing higher antibody
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human influenza vaccine in other animals is in progress.Materials and methods
Mice
Pathogen-free, female BALB/c mice were obtained from
Charles River (Charles River Wiga, Sulzfeld, Germany).
The animals were housed in a temperature-controlled
environment with 12-h light/dark cycles; food and water
were delivered ad libitum. Mice were immunized at 8 weeks
of age after 1-week adaptation in the animal room.
Influenza A strain
The strain X47 [A/Victoria/3/75 (H3N2)  A/Puerto
Rico/8/34 (H1N1)] was adapted to mice (m.a.) by a series of
lung passages, and one passage in embryonated chicken
eggs, as previously described (Neirynck et al., 1999). The
sequence of the M2-protein in the final preparation (before
aliquotting) was verified as identical to the original PR8-
strain (Fiers et al., 2001). This m.a. X47 preparation was
highly pathogenic; the dose lethal for 50% of the mice
(LD50) was 0.02 HAU.
Construction of expression vectors
Plasmid pKK223-3 (Amersham Pharmacia, UK) was
modified to include a unique NcoI restriction site, generat-
ing pKK223-3N, thereby enabling insertion of HBc genes as
NcoI–HindIII restriction fragments. A truncated HBc gene
(coding for amino acids 1 through 149) was modified by
PCR to contain a single C-terminal cysteine following
Val149 and cloned into pKK223-3N to generate the plasmid
pKK223-3N-1123, which expresses particle 1123. This
plasmid was further modified to accept the directional
insertion of synthetic dsDNA fragments. This was done by
introducing a SacI and an EcoRI restriction site between the
codons for Asp78 and Pro79 in the immunodominant loop
region (plasmid V16), or a SacI site between the codons for
Ile3 and Asp4 (plasmid V54). Particle 1559, which contains
a single copy of M2e fused to the N-terminus of full-length
HBc particles, is identical to IM2eHBc described previously
(Neirynck et al., 1999); however, it was produced using the
pKK223-3 expression system. A brief description of all the
constructs used is shown in Table 1.
Immunodominant loop insertion constructs (1473 and 1569)
Synthetic oligonucleotide fragments coding for amino
acids 2–24 of M2 were inserted into the immunodominant
loop insertion vector V16; the two endogenous cysteines at
positions 17 and 19 of M2e were mutated to either alanines
(1473) or serines (1569).N-terminal fusion constructs (1604, 1817, and 1818)
One, two, and three copies of M2e were fused to the
N-terminus of particle 1123 to generate particles 1604,
1817, and 1818, respectively. In all three cases, only the
N-terminal copy of M2e retained the initiator methionine at
position 1; the carrier-proximal copy of M2e retained the
cysteines at positions 17 and 19; all other copies contained
the M2e variant with cysteines 17 and 19 mutated to serines
(M2e(2C > 2S)). Plasmid V54 was digested with NcoI and
SacI to liberate the HBc sequence Met1Asp2Ile3, which was
replaced with the coding sequence for M2e(1–24) to yield
plasmid V54.M2e, which expresses particle 1604. A second
copy of M2e(1–24), in which the endogenous cysteine
residues in M2e were replaced by serine residues, was fused
to the N-terminus (without the initiator methionine) of the
particle specified by the V54.M2e vector, using PCR, to
yield the 1817-expressing plasmid V54.M2e(2C > 2S)/M2e.
To produce the 1818-expressing plasmid, V54.M2e(2C >
2S)/M2e(2C > 2S)/M2e, PCR was used to fuse a third copy
of M2e(1–24/2C > 2S) to the N-terminus (without the
initiator methionine) of the hybrid gene encoded by
V54.M2e(2C > 2S)/M2e.
Chemical conjugate (HBc/K77-M2e)
An expression vector encoding a modified 151 amino
acid HBc particle was constructed. The HBc subunit
contains a single lysine residue inserted between amino
acids 76 and 77 (see US Patent 6,231,864); it terminates at
position V149 of HBc, followed by a C-terminal cysteine
residue. A synthetic peptide corresponding to M2(2–24/
2C > 2S)–Gly–Gly–Gly–Cys (Multiple Peptide Systems,
San Diego CA, USA) was conjugated to HBc/K77 to
produce HBc/K77-M2e using published methods (Jegerleh-
ner et al., 2002).
Expression and purification of recombinant particles
Methods for expression and purification of recombinant
particles followed previously published protocols (Birkett et
al., 2002). Recombinant particles used as vaccine prepara-
tions in the present studies are listed in Table 1.
Adjuvants
To provide a comparison with previous results, we
immunized mice with particles formulated with MPL-
TDM emulsion (25 Ag monophosphoryl lipid A (MPL)
and 25 Ag synthetic trehalose-6,6-dimycolate (TDM) in an
oil-in-water emulsion) and boosted them twice with
particles formulated with 25 Ag MPL and 25 Ag muramyl
dipeptide (MDP, N-acetylmuramyl-l-alanyl-d-isoglut-
amine) (Neirynck et al., 1999). All products were obtained
from Sigma-Aldrich (St. Louis, MO, USA). A detoxified
mutant of heat-labile E. coli enterotoxin, LTR192G, was
M. De Filette et al. / Virology 337 (2005) 149–161 159used for intranasal (i.n.) administration; this preparation was
generously provided by Dr. J. Clements (Department of
Microbiology and Immunology, Tulane University Medical
Center, New Orleans, LA) (Dickinson and Clements, 1995;
Freytag and Clements, 1999). Montanide ISA-720 (SEPPIC
SA., 75, Quai d’Orcay, 75321 Paris, France) was used as per
manufacturer’s directions to generate water-in-oil emulsions
of M2e-HBc particles. For Alhydrogel (Superfos Biosector,
Denmark) formulations, particles were completely adsorbed
(>95%) using a 10% (v/v) solution of a 2.0% Alhydrogel
stock solution. For another formulation, Alhydrogel + RC-
529-AF, RC-529-AF (Corixa Corporation, Seattle WA,
USA) was added to Alhydrogel to a final concentration of
50 Ag/ml.
Immunization
Previous research had shown that within the range of
10–50 Ag, the amount of antigen used was not critical
(Neirynck et al., 1999). Therefore, in the present study,
M2e-HBc vaccine was kept constant at 10 Ag per injection
for both the i.p. and the i.n. routes of administration. The
total volume of the administered vaccine [M2e-HBc
construct + adjuvant in PBS (phosphate buffered saline)],
was 50 Al for i.n. administration (25 Al per nostril) and 100
Al for i.p. injection. Typically, an experiment involved 7 or 8
groups of 14–15 mice each. Three immunizations were
administered at 3-week intervals. Before the first, and 2
weeks after each immunization, blood samples were
collected by piercing of the ventral tail vein. The final
bleeding of surviving mice (2 weeks after challenge) was
performed by cardiac puncture. Blood clotting was allowed
to continue for 30 min at 37 -C; samples were placed on ice,
and serum was separated by collecting the supernatant of
two consecutive centrifugations.
Challenge and follow-up
Three weeks after the last immunization (second boost),
the mice were challenged with a 50-Al dose containing 4
LD50 (corresponding to 2.5  103 TCID50) of m.a. X47
influenza virus in buffer. This challenge dose was admin-
istered i.n. to mice lightly anesthetized by ether (experi-
ments shown in Figs. 1–5) or by isoflurane (experiments
shown in Figs. 6–8). Mortality was monitored on a daily
basis for 3 weeks. Morbidity was assessed by rectal
temperature and body weight.
Immunology
Antibody titers were determined by ELISA using sera
from individual mice, pooled sera from the group, or both.
To determine M2e-specific antibody titers, microtiter plates
(type II F96 MaxiSorp, Nunc) were coated with 50 Al of a 2
Ag/ml M2e-peptide solution in 50 mM sodium bicarbonate
buffer, pH 9.7, and incubated overnight at 37 -C. Afterwashing, the plates were blocked for 1 h with 200 Al of 1%
BSA in PBS. After 1-h incubation, the plates were washed
again. A series of 1/3 dilutions of the different serum
samples, starting with a 1/100 dilution, were loaded on the
peptide-coated plates. The bound antibodies were detected
with a peroxidase-labeled antibody directed against mouse
isotypes IgG1, IgG2a, IgG2b, or IgG3 (Southern Biotech-
nology Associates, Inc., Birmingham, AL, USA) and
diluted 1/6000 in PBS + 1% BSA + 0.05% Tween 20.
After washing, the microtiter plates were incubated for 5
min with TMB substrate (Tetramethylbenzidine, Sigma-
Aldrich). The reaction was stopped by addition of an equal
volume 1 M H3PO4 and the absorbance at 450 nm was
measured. Endpoint titers are defined as the highest dilution
producing an O.D. value twice that of background (pre-
immune serum). A similar procedure was followed for the
assay of M2e-specific IgA, except that the bound antibodies
were detected with a peroxidase-labeled antibody directed
against mouse IgA (Sigma-Aldrich), diluted 1/7000 in
PBS + 1% BSA + 0.05% Tween 20, and the incubation
with TMB substrate was 10 min.
The HBc-specific antibody titers were determined as
follows. The microtiter plates (type II F96 MaxiSorp,
Nunc) were coated with 100 Al of a 10 Ag/ml solution of
polyclonal rabbit antibody directed against HBc (DakoCy-
tomation, Carpinteria CA, USA) in 50 mM bicarbonate
buffer, pH 9.7, and incubated overnight at 4 -C. The plates
were washed and then blocked with 1% BSA in PBS. After
washing, capturing of HBc antigen (1 Ag/ml in PBS + 1%
BSA) was allowed to proceed for 1 h. The plates were
again washed, and a series of 1/3 dilutions of the different
serum samples, starting with a 1/100 dilution, were loaded
on the plates. The bound antibodies were detected with an
alkaline phosphatase-labeled antibody directed against
mouse IgG (Sigma-Aldrich), diluted 1/10000 in PBS +
1% BSA. After washing, the microtiter plates were
incubated for 60 min with p-nitrophenyl phosphate, and
the absorbance at 415 nm was measured. The endpoint
titers are defined as the highest dilution producing an O.D.
value twice that of background (pre-immune serum). A
similar procedure was used for determination of the HBc-
directed IgG1 titers.
Animal welfare
The animal facility operates under the Flemish Govern-
ment License Number LA1400091. All experiments were
done under conditions specified by law (European Directive
and Belgian Royal Decree of November 14, 1993) and
authorized by the Institutional Ethical Committee on
Experimental Animals.
Data analysis
Comparison of antibody titers between two experimental
groups was performed with the two-tailed Student’s t test.
M. De Filette et al. / Virology 337 (2005) 149–161160Comparison of more than two groups was done with the
Tukey multiple comparison test. This test compares the
difference between each pair of means with appropriate
adjustment for the multiple testing (Altman, 1991). Com-
parison of survival of mice after challenge was carried out
with the Kaplan–Meier test (Palmar and Machin, 1995).Acknowledgments
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